

Online supplementary materials

Supplementary Table 1. Result of the systematic review. Risk of bias is shown for randomization (RANDOM.), allocation (ALLOC.), blinding of participants (B PART.) and outcome (B OUTC.), completeness of outcome data (OUTCOME) and selective reporting (REPORT) and indicated as low (L), unclear (U) and high (H). BTX (botulinum toxin), SCI (spinal cord injury). When available, the molecule of BTX is reported: Abobotulinum toxin A (ABO), Incobotulinum toxin A (INC), Lanbotulinum toxin A (LAN), Neuronox (NEU), Onabotulinum toxin A (ONA), Prabotulinum toxin A (PRA), Rimabotulinum toxin B (RIM).

Part 1

Author, year	Disease	Tot. Pts.	Experimental group (EG)	way of admin. EG	Control group (CG)	way of admin. CG	Result (major effect)	RAND.	ALL.	B-PART.	B OUTC.	OUT-COME	REP.
Lee, 2022 [30]	spinal stenosis	100	50 U BTX + 30 mg triamcinolone + 0.8 mL 50% dextrose + 0.2 mL 4% lidocaine	intrarticular	30 mg triamcinolone + 2.5 mL 50% dextrose + 0.8 mL 2% lidocaine	transforam	BTX	U	L	L	L	L	U
Ahadi, 2022 [31]	plantar fasciitis	35	150 U ABO BTX	intramuscular	metilprednisolone	into the fascia	BTX	U	U	L	L	L	U
Chen, 2022 [32]	post-herpetic neuralgia	100	<= 200 U LAN BTX	subcutaneous	pulsed radiofrequency therapy	nerve root	no diff.	L	L	H	H	L	U
Dimitrova, 2022 [33]	cerebral palsy	381	1: 4 U/kg + physical therapy; 2: 8 U/kg ONA BTX + physical therapy	intramuscular	placebo	intramuscular	BTX	U	U	L	L	L	L
Tan, 2021 [34]	stroke and brain injury	36	100 U LAN BTX	intramuscular	placebo	intramuscular	BTX	L	L	L	L	L	U
Zirovich, 2021 [35]	headache	40	300 U ABO BTX	intramuscular	placebo	intramuscular	BTX	U	L	L	U	U	U
Levesque, 2021 [36]	pelvic dysfunction	80	50-300 U INC BTX + local anaesthetic	intramuscular	local anaesthetic	intramuscular	no diff.	L	L	L	L	L	U

Rezasol-tani, 2020 [37]	osteoarthritis	120	250 U ABO BTX	intrarticular	1: physical therapy; 2: hyaluronic acid; 3: 20% dextrose	intrarticular	BTX or dextrose	L	U	U	U	U	U
Lee, 2020 [38]	epicondylitis	60	10 U NEU BTX	intratendon	50 U NEU BTX	intratendon	50 U BTX	U	U	L	L	L	L
Kasapoğlu-Aksoy, 2020 [39]	stroke and brain injury	60	140-210 U ONA BTX	intramuscular	nerve block	perineural	no diff.	U	U	L	U	L	U
De Groef, 2020 [40]	oncologic	50	100 U ONA BTX	intramuscular	placebo	intramuscular	no diff.	L	L	L	L	L	L

Part 2

Author, year	Disease	Tot. Pts.	Experimental group (EG)	way of admin. EG	Control group (CG)	way of admin. CG	Result (major effect)	RAND.	ALL.	B-PART.	B-OUTC.	OUT-COME	REP.
Cahlin, 2019 [41]	cerebral palsy	12	100 U ONA BTX	intramuscular	placebo	intramuscular	no diff.	U	L	L	L	L	U
Chun, 2019 [42]	SCI	8	400 U ONA BTX	subcutaneous	placebo	subcutaneous	no diff.	U	L	L	L	H	U
Kütük, 2019 [43]	myofascial pain syndrome	40	25-150 U ABO BTX	intramuscular	dry needling	intramuscular	dry needling	U	U	U	U	U	U
Eleopra, 2018 [44]	osteoarthritis	46	400 U ABO BTX	intramuscular	placebo	intramuscular	BTX	L	L	L	L	L	L
De Groef, 2018 [45]	oncologic	50	100 U ONA BTX	intramuscular	placebo	intramuscular	BTX	L	L	L	L	L	L
Wein, 2018 [46]	stroke and brain injury	413	<= 400 U ONA BTX	intramuscular	placebo	intramuscular	BTX	L	L	L	L	L	U
Rosales, 2018 [47]	stroke and brain injury	42	500 U ABO BTX	intramuscular	placebo	intramuscular	BTX	U	L	L	U	L	L
Bao, 2018 [48]	osteoarthritis	60	100 U ONA BTX + exercise	intrarticular	1: placebo + exercise; 2: hyaluronic acid + exercise	intrarticular	BTX	U	U	H	L	L	U

Yi, 2018 [49]	cerebral palsy	16	<= 400 U NEU BTX	intramuscular	placebo	intramuscular	BTX	U	U	U	U	U	U
Creuzé, 2013 [50]	epicondylitis	60	40 U ABO BTX	intramuscular	placebo	intramuscular	BTX	L	U	L	L	L	U
Park, 2017 [51]	spinal stenosis	45	100 U PRA BTX	intramuscular	gabapentin	oral	BTX	U	U	H	H	U	U
Guo, 2017 [52]	epicondylitis	40	1: 20 U ONA BTX lateral epicondyle; 2: 20 U ONA BTX tender point	1: peritendon; 2: intramuscular	40 mg triamcinolone	peritendon	intramuscular BTX less effective	L	L	L	L	L	U

Part 3

Author, year	Disease	Tot. Pts.	Experimental group (EG)	way of admin. EG	Control group (CG)	way of admin. CG	Result (major effect)	RAND.	ALL.	B-PART.	B-OUTC.	OUT-COME	REP.
Hsieh, 2016 [53]	epicondylitis	46	100 U ONA BTX	intrarticular	education	-	BTX	L	U	H	H	L	U
Roca, 2016 [54]	plantar fasciitis	72	100 U ONA BTX	intrafascia	ESWT	foot sole	ESWT	L	U	H	L	L	U
Wissel, 2016 [55]	stroke and brain injury	273	(variable dosage) ONA BTX + standard care	intramuscular	placebo + standard care	intramuscular	BTX	U	U	L	U	U	U
Pasquina, 2016 [56]	amputation	9	10,000-20,000 U RIM BTX	intra-dermal	placebo	intra-dermal	no effects on pain	L	L	L	U	L	U
Han, 2016 [57]	SCI	40	200 U NEU BTX	subcutaneous	placebo	subcutaneous	BTX	L	L	L	L	L	U
Kwanchuay, 2015 [58]	myofascial pain syndrome	33	20 U ONA BTX	intramuscular	placebo	intramuscular	no diff.	U	L	L	L	L	U
Gracies, 2015 [59]	stroke and brain injury	243	1: 500 U ABO BTX; 2: 1000 U ABO BTX	intramuscular	placebo	intramuscular	BTX	L	L	L	L	L	L

Wu, 2015 [60]	other	16	130 U BTX	intramuscular	placebo	intramuscular	BTX	U	U	L	L	L	L
Tassorelli, 2014 [61]	other	26	50-200 U INC BTX + conventional therapy	intramuscular	placebo + conventional therapy	intramuscular	BTX	U	U	L	U	L	L
Gracies, 2014 [62]	stroke and brain injury	24	1: 10,000 U RIM BTX; 2: 15,000 U RIM BTX	intramuscular	placebo	intramuscular	15,000 U BTX	U	L	L	U	L	U
